Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL

Deal with long-time Australian partner could add up to $100 million to Merck's business in the 2010/2011 flu season, analyst says.

More from Archive

More from Pink Sheet